5 Most Undervalued NASDAQ Stocks to Buy Right Now

4. Biogen Inc. (NASDAQ:BIIB)

Number of Hedge Fund Holders: 64

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase II studies for Empaveli in treating delayed graft function and focal segmental glomerulosclerosis, citing strategic evaluations and recruitment challenges.

While the future of Apellis’ preclinical assets (such as its RNA-based therapies and gene-editing project) remains unclear, Biogen is maintaining its focus on a key Phase II trial for its eye disease therapy, Syfovre, in combination with an RNA interference inhibitor. This move indicates that Biogen’s primary interest lies in the established commercial value of the pegcetacoplan franchise, which is marketed as both Empaveli and Syfovre.

Biogen Inc.’s (NASDAQ:BIIB) strategic thinning of the pipeline appears designed to prioritize the most profitable assets acquired in the deal, with forecasts suggesting the pegcetacoplan franchise could generate $785 million by 2032. Although the company has not provided specific details regarding every program slated for closure, the shifts underscore a broader consolidation effort following the high-profile rare disease buyout.

Biogen Inc. (NASDAQ:BIIB) is a biopharmaceutical firm that works on identifying, making, and providing drugs for neurological and neurodegenerative diseases.

1281292 - 11759070 - 1